Glancy Binkow & Goldberg LLP Encourages Investors of Achillion Pharmaceuticals, Inc. with Losses of $250,000 or More to Contact the Firm Business Wire LOS ANGELES -- October 9, 2013 Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Achillion Pharmaceuticals, Inc. (“Achillion” or the “Company”) (NASDAQ:ACHN) concerning possible violations of federal securities laws. Investors with losses of $250,000 or more are encouraged to contact the firm for more information. Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at firstname.lastname@example.org to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased. Achillion is a biopharmaceutical company engaged in the discovery, development and commercialization of anti-infective drug therapies in the United States and internationally. The Company focuses on the development of antiviral therapies for the treatment of chronic hepatitis C viral (HCV) infection. One of the Company’s lead clinical-stage drug candidates is sovaprevir – a treatment for chronic HCV infection – designed for use in combination with other therapeutic products with complementary mechanisms of action. The investigation is related to allegations that the Company misrepresented or failed to disclose that sovaprevir did not interact well with other drugs commonly used to treat hepatitis or patients infected with both hepatitis and human immunodeficiency virus (HIV). On July 1, 2013, Achillion disclosed that the Food and Drug Administration instituted a clinical hold on sovaprevir after elevations in liver enzymes were noted in a “Phase I healthy subject drug-drug interaction study evaluating the effects of concomitant administration of sovaprevir with ritonavir-boosted atazanavir.” Subsequently, on September 27, 2013, the Company disclosed that the FDA had continued its clinical hold on sovaprevir after the agency concluded that “removal of the clinical hold is not warranted.” If you purchased Achillion shares between April 21, 2012 and September 27, 2013, if you have information or would like to learn more about these claims or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact: Glancy Binkow & Goldberg LLP, Los Angeles, CA Michael Goldberg (888) 773-9224 or Glancy Binkow & Goldberg LLP, New York, NY Gregory Linkh (212) 682-5340 firstname.lastname@example.org www.glancylaw.com
Glancy Binkow & Goldberg LLP Encourages Investors of Achillion Pharmaceuticals, Inc. with Losses of $250,000 or More to Contact
Press spacebar to pause and continue. Press esc to stop.